Duchenne News Tags: REGENXBIO

June 24, 2024
REGENXBIO shares a press release detailing updates on its Phase I/II AFFINITY DUCHENNE® trial.
May 10, 2024
REGENXBIO shares financial results for the first quarter ending March 31, 2024.
March 5, 2024
REGENXBIO reports additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne.
February 8, 2024
REGENXBIO announces completion of enrollment in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202.
November 30, 2023
REGENXBIO announces that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial.
November 9, 2023
On November 9, 2023, REGENXBIO announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, including a strategic pipeline prioritization and corporate restructuring intended to...
October 6, 2023
Regenxbio announces interim safety data and initial efficacy data from the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne.
April 12, 2023
REGENXBIO receives fast track designation for RGX-202 for the treatment of Duchenne
January 23, 2023
REGENXBIO announces Phase I/II AFFINITY DUCHENNE trial is active and recruiting patients

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open